MYF-01-37 |
Catalog No.GC63088 |
MYF-01-37 is a covalent TEAD inhibitor targeting Cys380. MYF-01-37 has a reversible inhibition on YAP/TEAD interaction.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2416417-65-5
Sample solution is provided at 25 µL, 10mM.
MYF-01-37 is a covalent TEAD inhibitor targeting Cys380. MYF-01-37 has a reversible inhibition on YAP/TEAD interaction[1].
MYF-01-37 (10 μM; 24h) results in inhibition of direct YAP/TEAD interaction in HEK 293T cells, and in the reduction in canonical YAP target gene CTGF expression in PC-9 cells[1]. MYF-01-37 (0.1, 1, 10, 100 μM) has minimal impact on cell viability of several EGFR-mutant NCSLC cell lines[1]. MYF-01-37 (10 μM; 10 days) combinated with OT (combination of osimertinib and trametinib) leads to a dramatic decrease in dormant cells compared to OT alone[1].
[1]. Kari J Kurppa, et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020 Jan 13;37(1):104-122.e12.
Average Rating: 5
(Based on Reviews and 7 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *